NasdaqCM:CORTPharmaceuticals
The Bull Case For Corcept Therapeutics (CORT) Could Change Following FDA Acceptance of Relacorilant Application – Learn Why
Corcept Therapeutics recently announced that the FDA has accepted its New Drug Application for relacorilant as a potential treatment for patients with platinum-resistant ovarian cancer, assigning a PDUFA date of July 11, 2026.
This regulatory milestone is based on positive Phase 2 and 3 trial data showing improved survival rates without added safety risks, and highlights relacorilant’s potential to address an unmet need in a difficult-to-treat cancer population.
We'll explore how the FDA's...